Copyright Reports & Markets. All rights reserved.

Global Biologics CMO (Contract Manufacturing Organization) Services Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Biologics CMO (Contract Manufacturing Organization) Services by Type
    • 1.3.1 Overview: Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Biologics CMO (Contract Manufacturing Organization) Services Consumption Value Market Share by Type in 2025
    • 1.3.3 Cell and Gene Therapies
    • 1.3.4 Antibodies
    • 1.3.5 Vaccines
    • 1.3.6 Others
  • 1.4 Classification of Biologics CMO (Contract Manufacturing Organization) Services by CMO Provider Type
    • 1.4.1 Overview: Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by CMO Provider Type: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Biologics CMO (Contract Manufacturing Organization) Services Consumption Value Market Share by CMO Provider Type in 2025
    • 1.4.3 In-house CMO
    • 1.4.4 Independent CMO
  • 1.5 Classification of Biologics CMO (Contract Manufacturing Organization) Services by Manufacturing Stage
    • 1.5.1 Overview: Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Manufacturing Stage: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Biologics CMO (Contract Manufacturing Organization) Services Consumption Value Market Share by Manufacturing Stage in 2025
    • 1.5.3 Drug Substance (DS) Manufacturing
    • 1.5.4 Drug Product (DP) Manufacturing
  • 1.6 Global Biologics CMO (Contract Manufacturing Organization) Services Market by Application
    • 1.6.1 Overview: Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Large Pharmaceutical and Biopharmaceutical Companies
    • 1.6.3 Small and Mid-sized Pharmaceutical and Biotechnology Companies
    • 1.6.4 Others
  • 1.7 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size & Forecast
  • 1.8 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast by Region
    • 1.8.1 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Biologics CMO (Contract Manufacturing Organization) Services Market Size by Region, (2021-2032)
    • 1.8.3 North America Biologics CMO (Contract Manufacturing Organization) Services Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Biologics CMO (Contract Manufacturing Organization) Services Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Market Size and Prospect (2021-2032)
    • 1.8.6 South America Biologics CMO (Contract Manufacturing Organization) Services Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Biologics CMO (Contract Manufacturing Organization) Services Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Lonza Group AG
    • 2.1.1 Lonza Group AG Details
    • 2.1.2 Lonza Group AG Major Business
    • 2.1.3 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.1.4 Lonza Group AG Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Lonza Group AG Recent Developments and Future Plans
  • 2.2 Samsung Biologics Co., Ltd.
    • 2.2.1 Samsung Biologics Co., Ltd. Details
    • 2.2.2 Samsung Biologics Co., Ltd. Major Business
    • 2.2.3 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.2.4 Samsung Biologics Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Samsung Biologics Co., Ltd. Recent Developments and Future Plans
  • 2.3 FUJIFILM Biotechnologies
    • 2.3.1 FUJIFILM Biotechnologies Details
    • 2.3.2 FUJIFILM Biotechnologies Major Business
    • 2.3.3 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.3.4 FUJIFILM Biotechnologies Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 FUJIFILM Biotechnologies Recent Developments and Future Plans
  • 2.4 Boehringer Ingelheim
    • 2.4.1 Boehringer Ingelheim Details
    • 2.4.2 Boehringer Ingelheim Major Business
    • 2.4.3 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.4.4 Boehringer Ingelheim Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Boehringer Ingelheim Recent Developments and Future Plans
  • 2.5 WuXi Biologics (Cayman) Inc.
    • 2.5.1 WuXi Biologics (Cayman) Inc. Details
    • 2.5.2 WuXi Biologics (Cayman) Inc. Major Business
    • 2.5.3 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.5.4 WuXi Biologics (Cayman) Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 WuXi Biologics (Cayman) Inc. Recent Developments and Future Plans
  • 2.6 Thermo Fisher Scientific
    • 2.6.1 Thermo Fisher Scientific Details
    • 2.6.2 Thermo Fisher Scientific Major Business
    • 2.6.3 Thermo Fisher Scientific Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.6.4 Thermo Fisher Scientific Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.7 Catalent, Inc.
    • 2.7.1 Catalent, Inc. Details
    • 2.7.2 Catalent, Inc. Major Business
    • 2.7.3 Catalent, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.7.4 Catalent, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Catalent, Inc. Recent Developments and Future Plans
  • 2.8 AGC Biologics
    • 2.8.1 AGC Biologics Details
    • 2.8.2 AGC Biologics Major Business
    • 2.8.3 AGC Biologics Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.8.4 AGC Biologics Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 AGC Biologics Recent Developments and Future Plans
  • 2.9 National Resilience, Inc.
    • 2.9.1 National Resilience, Inc. Details
    • 2.9.2 National Resilience, Inc. Major Business
    • 2.9.3 National Resilience, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.9.4 National Resilience, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 National Resilience, Inc. Recent Developments and Future Plans
  • 2.10 Vetter Pharma International GmbH
    • 2.10.1 Vetter Pharma International GmbH Details
    • 2.10.2 Vetter Pharma International GmbH Major Business
    • 2.10.3 Vetter Pharma International GmbH Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.10.4 Vetter Pharma International GmbH Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Vetter Pharma International GmbH Recent Developments and Future Plans
  • 2.11 Rentschler Biopharma SE
    • 2.11.1 Rentschler Biopharma SE Details
    • 2.11.2 Rentschler Biopharma SE Major Business
    • 2.11.3 Rentschler Biopharma SE Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.11.4 Rentschler Biopharma SE Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Rentschler Biopharma SE Recent Developments and Future Plans
  • 2.12 KBI Biopharma, Inc.
    • 2.12.1 KBI Biopharma, Inc. Details
    • 2.12.2 KBI Biopharma, Inc. Major Business
    • 2.12.3 KBI Biopharma, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.12.4 KBI Biopharma, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 KBI Biopharma, Inc. Recent Developments and Future Plans
  • 2.13 LOTTE BIOLOGICS Co., Ltd.
    • 2.13.1 LOTTE BIOLOGICS Co., Ltd. Details
    • 2.13.2 LOTTE BIOLOGICS Co., Ltd. Major Business
    • 2.13.3 LOTTE BIOLOGICS Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.13.4 LOTTE BIOLOGICS Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 LOTTE BIOLOGICS Co., Ltd. Recent Developments and Future Plans
  • 2.14 Pfizer CentreOne
    • 2.14.1 Pfizer CentreOne Details
    • 2.14.2 Pfizer CentreOne Major Business
    • 2.14.3 Pfizer CentreOne Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.14.4 Pfizer CentreOne Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Pfizer CentreOne Recent Developments and Future Plans
  • 2.15 AbbVie Contract Manufacturing
    • 2.15.1 AbbVie Contract Manufacturing Details
    • 2.15.2 AbbVie Contract Manufacturing Major Business
    • 2.15.3 AbbVie Contract Manufacturing Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.15.4 AbbVie Contract Manufacturing Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 AbbVie Contract Manufacturing Recent Developments and Future Plans
  • 2.16 Syngene International Limited
    • 2.16.1 Syngene International Limited Details
    • 2.16.2 Syngene International Limited Major Business
    • 2.16.3 Syngene International Limited Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.16.4 Syngene International Limited Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Syngene International Limited Recent Developments and Future Plans
  • 2.17 Avid Bioservices, Inc.
    • 2.17.1 Avid Bioservices, Inc. Details
    • 2.17.2 Avid Bioservices, Inc. Major Business
    • 2.17.3 Avid Bioservices, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.17.4 Avid Bioservices, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Avid Bioservices, Inc. Recent Developments and Future Plans
  • 2.18 Recipharm Advanced Bio
    • 2.18.1 Recipharm Advanced Bio Details
    • 2.18.2 Recipharm Advanced Bio Major Business
    • 2.18.3 Recipharm Advanced Bio Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.18.4 Recipharm Advanced Bio Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Recipharm Advanced Bio Recent Developments and Future Plans
  • 2.19 Ajinomoto Bio-Pharma Services
    • 2.19.1 Ajinomoto Bio-Pharma Services Details
    • 2.19.2 Ajinomoto Bio-Pharma Services Major Business
    • 2.19.3 Ajinomoto Bio-Pharma Services Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.19.4 Ajinomoto Bio-Pharma Services Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Ajinomoto Bio-Pharma Services Recent Developments and Future Plans
  • 2.20 Wacker Biotech GmbH
    • 2.20.1 Wacker Biotech GmbH Details
    • 2.20.2 Wacker Biotech GmbH Major Business
    • 2.20.3 Wacker Biotech GmbH Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.20.4 Wacker Biotech GmbH Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Wacker Biotech GmbH Recent Developments and Future Plans
  • 2.21 Bora Biologics
    • 2.21.1 Bora Biologics Details
    • 2.21.2 Bora Biologics Major Business
    • 2.21.3 Bora Biologics Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.21.4 Bora Biologics Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.21.5 Bora Biologics Recent Developments and Future Plans
  • 2.22 3PBIOVIAN
    • 2.22.1 3PBIOVIAN Details
    • 2.22.2 3PBIOVIAN Major Business
    • 2.22.3 3PBIOVIAN Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.22.4 3PBIOVIAN Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.22.5 3PBIOVIAN Recent Developments and Future Plans
  • 2.23 Fareva
    • 2.23.1 Fareva Details
    • 2.23.2 Fareva Major Business
    • 2.23.3 Fareva Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.23.4 Fareva Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.23.5 Fareva Recent Developments and Future Plans
  • 2.24 Aenova Group
    • 2.24.1 Aenova Group Details
    • 2.24.2 Aenova Group Major Business
    • 2.24.3 Aenova Group Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.24.4 Aenova Group Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.24.5 Aenova Group Recent Developments and Future Plans
  • 2.25 Siegfried Holding AG
    • 2.25.1 Siegfried Holding AG Details
    • 2.25.2 Siegfried Holding AG Major Business
    • 2.25.3 Siegfried Holding AG Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.25.4 Siegfried Holding AG Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.25.5 Siegfried Holding AG Recent Developments and Future Plans
  • 2.26 GenScript ProBio
    • 2.26.1 GenScript ProBio Details
    • 2.26.2 GenScript ProBio Major Business
    • 2.26.3 GenScript ProBio Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.26.4 GenScript ProBio Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.26.5 GenScript ProBio Recent Developments and Future Plans
  • 2.27 Chime Biologics (Wuhan) Co., Ltd.
    • 2.27.1 Chime Biologics (Wuhan) Co., Ltd. Details
    • 2.27.2 Chime Biologics (Wuhan) Co., Ltd. Major Business
    • 2.27.3 Chime Biologics (Wuhan) Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.27.4 Chime Biologics (Wuhan) Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.27.5 Chime Biologics (Wuhan) Co., Ltd. Recent Developments and Future Plans
  • 2.28 MabPlex International
    • 2.28.1 MabPlex International Details
    • 2.28.2 MabPlex International Major Business
    • 2.28.3 MabPlex International Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.28.4 MabPlex International Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.28.5 MabPlex International Recent Developments and Future Plans
  • 2.29 Pharmaron Beijing Co., Ltd.
    • 2.29.1 Pharmaron Beijing Co., Ltd. Details
    • 2.29.2 Pharmaron Beijing Co., Ltd. Major Business
    • 2.29.3 Pharmaron Beijing Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.29.4 Pharmaron Beijing Co., Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.29.5 Pharmaron Beijing Co., Ltd. Recent Developments and Future Plans
  • 2.30 Thousand Oaks Biologics Inc.
    • 2.30.1 Thousand Oaks Biologics Inc. Details
    • 2.30.2 Thousand Oaks Biologics Inc. Major Business
    • 2.30.3 Thousand Oaks Biologics Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.30.4 Thousand Oaks Biologics Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.30.5 Thousand Oaks Biologics Inc. Recent Developments and Future Plans
  • 2.31 Cytovance Biologics, Inc.
    • 2.31.1 Cytovance Biologics, Inc. Details
    • 2.31.2 Cytovance Biologics, Inc. Major Business
    • 2.31.3 Cytovance Biologics, Inc. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.31.4 Cytovance Biologics, Inc. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.31.5 Cytovance Biologics, Inc. Recent Developments and Future Plans
  • 2.32 Porton Pharma Solutions Ltd.
    • 2.32.1 Porton Pharma Solutions Ltd. Details
    • 2.32.2 Porton Pharma Solutions Ltd. Major Business
    • 2.32.3 Porton Pharma Solutions Ltd. Biologics CMO (Contract Manufacturing Organization) Services Product and Solutions
    • 2.32.4 Porton Pharma Solutions Ltd. Biologics CMO (Contract Manufacturing Organization) Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.32.5 Porton Pharma Solutions Ltd. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Biologics CMO (Contract Manufacturing Organization) Services Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Biologics CMO (Contract Manufacturing Organization) Services by Company Revenue
    • 3.2.2 Top 3 Biologics CMO (Contract Manufacturing Organization) Services Players Market Share in 2025
    • 3.2.3 Top 6 Biologics CMO (Contract Manufacturing Organization) Services Players Market Share in 2025
  • 3.3 Biologics CMO (Contract Manufacturing Organization) Services Market: Overall Company Footprint Analysis
    • 3.3.1 Biologics CMO (Contract Manufacturing Organization) Services Market: Region Footprint
    • 3.3.2 Biologics CMO (Contract Manufacturing Organization) Services Market: Company Product Type Footprint
    • 3.3.3 Biologics CMO (Contract Manufacturing Organization) Services Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Biologics CMO (Contract Manufacturing Organization) Services Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Biologics CMO (Contract Manufacturing Organization) Services Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Biologics CMO (Contract Manufacturing Organization) Services Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Biologics CMO (Contract Manufacturing Organization) Services Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Type (2021-2032)
  • 6.2 North America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Application (2021-2032)
  • 6.3 North America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
    • 6.3.1 North America Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Country (2021-2032)
    • 6.3.2 United States Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Type (2021-2032)
  • 7.2 Europe Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Application (2021-2032)
  • 7.3 Europe Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
    • 7.3.1 Europe Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 7.3.3 France Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Market Size by Region
    • 8.3.1 Asia-Pacific Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Region (2021-2032)
    • 8.3.2 China Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 8.3.5 India Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Type (2021-2032)
  • 9.2 South America Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Application (2021-2032)
  • 9.3 South America Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
    • 9.3.1 South America Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Biologics CMO (Contract Manufacturing Organization) Services Market Size by Country
    • 10.3.1 Middle East & Africa Biologics CMO (Contract Manufacturing Organization) Services Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Biologics CMO (Contract Manufacturing Organization) Services Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Biologics CMO (Contract Manufacturing Organization) Services Market Drivers
  • 11.2 Biologics CMO (Contract Manufacturing Organization) Services Market Restraints
  • 11.3 Biologics CMO (Contract Manufacturing Organization) Services Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Biologics CMO (Contract Manufacturing Organization) Services Industry Chain
  • 12.2 Biologics CMO (Contract Manufacturing Organization) Services Upstream Analysis
  • 12.3 Biologics CMO (Contract Manufacturing Organization) Services Midstream Analysis
  • 12.4 Biologics CMO (Contract Manufacturing Organization) Services Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Biologics CMO (Contract Manufacturing Organization) Services market size was valued at US$ 22420 million in 2025 and is forecast to a readjusted size of US$ 39406 million by 2032 with a CAGR of 8.5% during review period.
    Biologics CMO (Contract Manufacturing Organization) Services refer to manufacturing services provided by contract manufacturing organizations under client agreements to biopharmaceutical companies, pharmaceutical companies, and other drug development organizations. These services primarily include biologic drug substance manufacturing, drug product manufacturing, aseptic fill-finish, and other GMP manufacturing activities. The service scope covers antibodies, vaccines, cell and gene therapies, and other biologics, and may support both clinical-stage and commercial-stage production. The market includes contract manufacturing services provided by independent third-party CMOs as well as external manufacturing services offered by in-house CMO business units of pharmaceutical and biopharmaceutical companies. Compared with CDMO services, CMO services are primarily focused on manufacturing execution and production capabilities and generally do not emphasize early-stage drug development, comprehensive process development, formulation development, or other R&D-intensive activities.
    Biologics CMO (Contract Manufacturing Organization) services refer to GMP manufacturing services provided under contract to pharmaceutical companies, biotechnology companies, and other drug development organizations. These services primarily cover biologic drug substance (DS) manufacturing, drug product (DP) manufacturing, aseptic fill-finish, packaging, and related quality control activities. By provider type, the industry includes both independent CMOs whose core business is third-party contract manufacturing and in-house CMO business units of large pharmaceutical and biopharmaceutical companies that provide manufacturing capacity to external customers. Compared with CDMOs, CMOs place greater emphasis on process execution following technology transfer, scale-up manufacturing, quality control, and reliable supply, while early-stage drug discovery, systematic process development, and formulation development are generally not their primary functions.
    By product type, biologics CMO services mainly cover antibodies, vaccines, cell and gene therapies, and other biologics. Antibodies represent one of the more mature contract manufacturing segments and typically involve mammalian cell culture, harvest, chromatography purification, viral clearance, and drug substance preparation. Vaccine manufacturing involves a wider range of production platforms and process technologies. Cell and gene therapies generally feature smaller batch sizes, more complex processes, stringent quality requirements, and highly customized manufacturing workflows. Consequently, facility design, equipment configuration, biosafety requirements, and quality systems vary significantly across different biologic modalities.
    By manufacturing stage, the industry can be divided into biologic drug substance manufacturing and biologic drug product manufacturing. Drug substance manufacturing is generally the more technology- and capital-intensive segment and includes cell culture or microbial fermentation, separation, purification, and bulk drug substance storage. Drug product manufacturing primarily covers formulation, aseptic filling, lyophilization, and filling into vials, prefilled syringes, or cartridges. Some large CMOs have established integrated DS-to-DP manufacturing networks, while other specialized providers focus on large-scale drug substance manufacturing or specific activities such as sterile fill-finish.
    Direct customers primarily include large pharmaceutical and biopharmaceutical companies, small and mid-sized pharmaceutical and biotechnology companies, and other drug development organizations. Large pharmaceutical companies generally maintain internal manufacturing capabilities but may outsource production due to capacity constraints, new product introductions, regional supply requirements, specialized manufacturing needs, or efforts to reduce fixed-asset investment. Small and mid-sized biotechnology companies tend to rely more heavily on external manufacturing resources, with CMOs supporting clinical supply, scale-up, and commercial production.
    Biologics CMO is an industry characterized by high capital, technical, and regulatory barriers. Mammalian cell culture is a core platform for antibodies and many recombinant proteins. Commercial manufacturing commonly utilizes individual bioreactors ranging from approximately 2,000 L to 20,000 L, while large-scale commercial facilities typically combine multiple bioreactors into a production train. Effective annual capacity per production line depends on the number of bioreactors, culture cycle, product titer, batch success rate, and facility utilization. Single-use bioreactors offer shorter construction timelines, greater flexibility for product changeover, and lower cross-contamination risk, while large stainless-steel systems continue to provide significant economies of scale for mature, high-volume commercial products.
    The upstream supply chain primarily consists of cell culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins and columns, buffer materials, and sterile packaging components. Critical materials such as culture media, single-use consumables, and high-performance chromatography media can materially affect batch consistency and product quality. Major CMOs therefore typically establish multi-supplier strategies and safety stocks for critical materials while increasing facility utilization through standardized platform processes.
    Regulatory compliance and quality systems constitute major competitive barriers. Biologics manufacturing must continuously comply with GMP requirements and maintain robust systems for quality management, data integrity, contamination control, process validation, and batch release. Once a commercial product has received regulatory approval and its manufacturing process has been validated at a specific CMO facility, transferring production to another site generally requires additional technology transfer, validation, and regulatory change procedures. The associated time and cost create relatively high customer stickiness and long contract durations for established commercial products.
    Key competitive factors include commercial manufacturing experience, GMP compliance track record, manufacturing scale, capacity utilization, technology transfer efficiency, batch success rates, delivery reliability, and global manufacturing networks. Large CMOs with extensive bioreactor capacity and multiple manufacturing sites are well positioned to serve high-volume commercial antibody products, while mid-sized and specialized CMOs differentiate themselves through flexible capacity, small-batch manufacturing, complex molecule capabilities, or specialized technology platforms.
    Profitability varies significantly depending on product type, manufacturing scale, capacity utilization, and development stage. Mature commercial biologics generally provide more stable batch demand and higher equipment utilization, whereas clinical-stage projects involve smaller batch volumes, frequent product changeovers, and greater project attrition. Gross margins for established biologics CMO manufacturing operations can generally fall within approximately 20%–40%. Large-scale antibody drug substance manufacturing can achieve stronger economies of scale at high utilization rates, while cell and gene therapy manufacturing and small-batch sterile fill-finish may command higher unit pricing but also require greater labor, quality control, and facility costs.
    Future industry growth will be supported by the continued expansion of biologics pipelines, increasing commercialization of antibody drugs and emerging biologic modalities, efforts by pharmaceutical companies to reduce fixed-asset investment, and deeper specialization across pharmaceutical manufacturing networks. At the same time, major CMOs continue to add large-scale 20,000 L-class mammalian cell culture capacity, resulting in greater capacity availability in certain regions. Competition is therefore expected to gradually shift from pure capacity expansion toward a broader focus on capacity utilization, manufacturing efficiency, quality consistency, supply reliability, and lifecycle manufacturing capabilities.
    Report Scope
    This report is a detailed and comprehensive analysis for global Biologics CMO (Contract Manufacturing Organization) Services market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Biologics CMO (Contract Manufacturing Organization) Services market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Biologics CMO (Contract Manufacturing Organization) Services market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Biologics CMO (Contract Manufacturing Organization) Services market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Biologics CMO (Contract Manufacturing Organization) Services market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Biologics CMO (Contract Manufacturing Organization) Services
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Biologics CMO (Contract Manufacturing Organization) Services market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza Group AG, Samsung Biologics Co., Ltd., FUJIFILM Biotechnologies, Boehringer Ingelheim, WuXi Biologics (Cayman) Inc., Thermo Fisher Scientific, Catalent, Inc., AGC Biologics, National Resilience, Inc., Vetter Pharma International GmbH, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Biologics CMO (Contract Manufacturing Organization) Services market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Market segment by Type
    Cell and Gene Therapies
    Antibodies
    Vaccines
    Others
    Market segment by CMO Provider Type
    In-house CMO
    Independent CMO
    Market segment by Manufacturing Stage
    Drug Substance (DS) Manufacturing
    Drug Product (DP) Manufacturing
    Market segment by Application
    Large Pharmaceutical and Biopharmaceutical Companies
    Small and Mid-sized Pharmaceutical and Biotechnology Companies
    Others
    Market segment by players, this report covers
    Lonza Group AG
    Samsung Biologics Co., Ltd.
    FUJIFILM Biotechnologies
    Boehringer Ingelheim
    WuXi Biologics (Cayman) Inc.
    Thermo Fisher Scientific
    Catalent, Inc.
    AGC Biologics
    National Resilience, Inc.
    Vetter Pharma International GmbH
    Rentschler Biopharma SE
    KBI Biopharma, Inc.
    LOTTE BIOLOGICS Co., Ltd.
    Pfizer CentreOne
    AbbVie Contract Manufacturing
    Syngene International Limited
    Avid Bioservices, Inc.
    Recipharm Advanced Bio
    Ajinomoto Bio-Pharma Services
    Wacker Biotech GmbH
    Bora Biologics
    3PBIOVIAN
    Fareva
    Aenova Group
    Siegfried Holding AG
    GenScript ProBio
    Chime Biologics (Wuhan) Co., Ltd.
    MabPlex International
    Pharmaron Beijing Co., Ltd.
    Thousand Oaks Biologics Inc.
    Cytovance Biologics, Inc.
    Porton Pharma Solutions Ltd.
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Biologics CMO (Contract Manufacturing Organization) Services product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Biologics CMO (Contract Manufacturing Organization) Services, with revenue, gross margin, and global market share of Biologics CMO (Contract Manufacturing Organization) Services from 2021 to 2026.
    Chapter 3, the Biologics CMO (Contract Manufacturing Organization) Services competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biologics CMO (Contract Manufacturing Organization) Services market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics CMO (Contract Manufacturing Organization) Services.
    Chapter 13, to describe Biologics CMO (Contract Manufacturing Organization) Services research findings and conclusion.

    Buy now